Phreesia opened higher at $12.87, compared with its previous close of $12.81. In the last trading session, the stock traded between $12.50 and $12.97. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Phreesia is now worth
$ 17.10
Resulting in a loss of
$ 82.90 (82.90%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
50%
Hold
41.67%
Sell
8.33%
Markets Today
Today's Change
$-0.20 (-1.52%)
Day High
$12.97
Day Low
$12.50
Day Open
$12.87
Prev Close
$12.81
Volume
6,46,301
1W Return
-4.32%
1M Return
16.46%
3M Return
2.74%
6M Return
31.82%
1Y Return
-44.55%
Fundamentals
Market Cap ($ Mn)
783
PE Ratio
81.00
PB Ratio
2.09
PEG Ratio
-
ROE
0.77%
ROCE
-1.24%
EPS (TTM)
$0.03
Investment Returns
1 Week
-4.32%
1 Month
16.46%
3 Months
2.74%
6 Months
31.82%
9 Months
0.92%
Financials
Quarterly
All values in $ Mn
115.9
Apr 25
117.3
Jul 25
120.3
Oct 25
127.1
Jan 26
130.9
Apr 26
129.5
Jul 26
Updates
11Nov
JP Morgan downgrades Phreesia to Underweight with $13 price target
JP Morgan downgraded Phreesia from Neutral to Underweight. Analyst Alexei Gogolev set a new price target of $13. Rating change reflects a cautious outlook on the stock.
Yesterday
14Sep
Phreesia integrates ProviderConnect data into DeepIntent marketplace
Phreesia partners with DeepIntent to integrate ProviderConnect audiences. Tool targets clinicians based on upcoming patient cases and real-world data. Aims to reach providers before treatment decisions are made. Phreesia enabled over 180 million patient visits in 2025.
1mo ago
8Sep
Raymond James downgrades Phreesia to Market Perform
Raymond James downgraded Phreesia from Outperform to Market Perform. Analyst John Ransom led the rating change for the NYSE-listed firm. No financial metrics or price targets were disclosed alongside the move.
2mo ago
4Sep
Phreesia files shelf prospectus for potential offering
Phreesia filed a shelf registration statement with the SEC. The filing enables future securities offerings without individual registration. Specific offering size and terms were not disclosed in the document.
2mo ago
3Sep
Phreesia Q2 revenue beats estimate but EPS miss weighs on stock
Phreesia Q2FY27 revenue of $129.458 million beat estimates by 0.30%. EPS of $0.03 missed the $0.10 consensus estimate by 70%. Shares fell 5.6% to $11.21 following the results release. Wells Fargo raised PT to $10; Needham and RBC maintained Buy/Outperform ratings. Company reaffirmed FY27 revenue guidance of $510-$520 million.
2mo ago
3Sep
Needham Reiterates Buy on Phreesia, Maintains $14 Price Target
Needham analyst Ryan MacDonald reiterates Buy rating on Phreesia (NYSE: PHR). Price target maintained at $14, unchanged from previous coverage. No new financial estimates or operational metrics disclosed in update. Analysts maintain positive outlook on healthcare IT provider.
